Novel In Vitro Granuloma Model for Studying Tuberculosis and Drug Efficacy

Description:
CDC researchers have developed an in vitro model system designed to simulate early-stage Mycobacterium tuberculosis infection and induced granuloma formation. This modeling platform can be used for studying tuberculosis pathogenicity, identifying phenotypically-interesting clinical isolates, studying early-stage host cytokine/chemokine responses, and in vitro candidate-drug screening. The approach incorporates autologous human macrophages, human peripheral blood mononuclear cells, and mycobacteria to mimic in situ granuloma formation in a controllable in vitro environment. This technology would be broadly useful for investigations into the numerous facets of early granuloma host-pathogen interaction, ultimately leading to improved prevention, intervention, and treatment strategies.
Patent Information:
For Information, Contact:
Jeremiah Mitzelfelt
NIH Technology Transfer
301-443-8518
jeremiah.mitzelfelt@nih.gov
Inventors:
Manon Deslauriers
Kristin Birkness
Peter King
Bernard Beall
Frederick Quinn
Keywords:
AC4XXX
AC5XXX
ACXXXX
ANTIGENS
AXXXXX
CDC Docket Import
CDC Docket Import CDC Prosecuting
DA3XXX
DAXXXX
DC4XXX
DCXXXX
DDXXXX
DEXXXX
diagnostic
DXXXXX
Granuloma
Human
IA3XXX
Identification
Latent
Methods
Model
OID-NCHHSTP-DTE
TUBERCULOSIS
Vitro
VJXXXX
WBXXXX
WFXXXX
WIXXXX
WMXXXX
XHXXXX
YBXXXX
YFXXXX
© 2024. All Rights Reserved. Powered by Inteum